Flatiron Health

Flatiron Health is a wholly owned subsidiary of Roche. Its CEO as of 2025 is Caroline Pavis, who succeeded founder Nat Turner in 2021. Investment in the platform and product development decisions are made by Flatiron's executive team, which includes a chief medical officer, chief technology officer, and chief commercial officer. Roche's diagnostics division holds strategic oversight but delegates daily operational control.

Flatiron Health sources clinical data through a network of over 280 community and academic oncology practices that use its electronic health record (EHR) software, Flatiron OncoEMR. Data is ingested in near real-time via direct EHR integration. The company also partners with genomic testing labs and claims data providers to enrich its dataset. All data is de-identified and used under patient consent and HIPAA-compliant protocols.

Neither. Flatiron Health is not a family office or investment firm. It is a healthcare technology and data analytics company. Its structure is a regulated medical device company (the EHR) combined with a data-as-a-service business for life sciences. The firm does not manage external capital or deploy funds; it generates revenue through software licenses, data subscription fees, and consulting services. Its ownership by Roche does not change its operating model.

Flatiron Health does not make investments. As a commercial entity, its stage focus is on scaling adoption among oncology practices and life sciences clients. Its product development targets later-stage clinical trial support — Phase III and post-market — but its data network also supports early-stage research such as biomarker discovery and trial site selection.

Flatiron Health avoids any therapeutic area outside oncology. It does not build or license EHRs for non-cancer specialties. The company also avoids direct patient-facing applications, such as telemedicine or consumer health apps, and does not operate in the insurance or payer market. Its data licensing agreements specifically exclude use in insurance underwriting or risk-scoring.

Flatiron Health is a wholly owned subsidiary of Roche, acquired in 2018 for $1.9B (per Roche, 2018). Roche's diagnostics division owns the company. Flatiron operates as an independent subsidiary with its own board, executive team, and P&L. Roche uses Flatiron's data platform to accelerate drug development and co-markets Flatiron's EHR to oncology clinics through its global commercial network. The two entities share no commingled funds or investment vehicles.

Flatiron Health does not operate a public foundation or charitable arm. The company provides free or discounted software to certain community clinics through its access program, but this is a business development initiative rather than a philanthropic structure. Roche separately maintains the Roche Foundation, which is not directly affiliated with Flatiron Health.